LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)
Titel:
LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)
Auteur:
Jhaveri, K. Juric, D. Yap, Y-S. Cresta, S. Layman, R. Duhoux, F. Terret, C. De Vita, S. Kundamal, N. He, W. Balbin, A. Sheng, Q. Crystal, A. Curigliano, G.